Hansoh Pharmaceutical Group Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Huijuan Zhong

Geschäftsführender

CN¥14.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	49.6%
Amtszeit als Geschäftsführer	8.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	8.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Huijuan Zhong im Vergleich zu den Einnahmen von Hansoh Pharmaceutical Group verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	CN¥5b
Mar 31 2024	n/a	n/a	CN¥4b
Dec 31 2023	CN¥15m	CN¥7m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥11m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥16m	CN¥8m	CN¥3b

Vergütung im Vergleich zum Markt: HuijuanDie Gesamtvergütung ($USD2.08M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD789.58K).

Entschädigung vs. Einkommen: HuijuanDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Huijuan Zhong (63 yo)

8.8yrs

Amtszeit

CN¥14,807,000

Vergütung

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	keine Daten
Aifeng Lyu	Executive Director	8.5yrs	CN¥9.39m	0.023% CN¥ 27.9m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% CN¥ 25.0m
Min Hu	VP & CFO	no data	keine Daten	keine Daten
Chih-Hung Lee	Chief of Science Officer	2.4yrs	keine Daten	keine Daten
Chuanhe Xu	Senior Vice President	15.5yrs	keine Daten	keine Daten
Weiyong Sun	Chief Commercial Officer	no data	keine Daten	keine Daten
Shengli Zhong	Joint Company Secretary & Senior VP	6.1yrs	keine Daten	keine Daten
Sze Wai Tam	Joint Company Secretary	less than a year	keine Daten	keine Daten

8.5yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: 3692Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	keine Daten
Aifeng Lyu	Executive Director	8.5yrs	CN¥9.39m	0.023% CN¥ 27.9m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% CN¥ 25.0m
Guoqiang Lin	Independent Non-Executive Director	5.3yrs	CN¥360.00k	keine Daten
Sheung Wai Chan	Independent Non-Executive Director	5.3yrs	CN¥360.00k	keine Daten
Dongtao Yang	Independent Non-Executive Director	5.3yrs	CN¥360.00k	keine Daten

6.9yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: 3692Die Vorstandsmitglieder gelten als erfahren (6.8 Jahre durchschnittliche Amtszeit).

Hansoh Pharmaceutical Group Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 22% undervalued

Upcoming dividend of HK$0.14 per share

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.7% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10383 tablets"

Hansoh Pharmaceutical Group Company Limited Announces That "Ibrexafungerp Tablets" Has Been Granted A Clinical Trial

Non-Executive Director Cuifang Ma has left the company

First half 2021 earnings released: EPS CN¥0.22 (vs CN¥0.21 in 1H 2020)

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Receives Approval by the National Medical Products Administration of the People ' S Republic of China for Class 1 Innovative Drug Tenofovir Amibufenamide Tablets

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ameile for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Hansoh Pharmaceutical Group Company Limited Announces FDA Tentative Approval of "Bortezomib for Injection"

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019)

Hansoh Pharmaceutical Group Company Limited Recommends a Final Dividend for the Year Ended December 31, 2020, Payable on July 5, 2021

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.47 in FY 2019)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in China